Clinical trial
A Phase-3, Randomized, Parallel Group, Open-label, Multicenter, Two-Arm Treatment Study to Evaluate the Efficacy and Safety of Weekly Paclitaxel Lipid Suspension Compared with Weekly Conventional Paclitaxel in the Patients with Platinum-Resistant/Refractory Recurrent High-grade Serous Epithelial Ovarian Cancer Including Fallopian Tube And/or Primary Peritoneal Cancer
NCT06867562 is registered in ClinicalTrials.gov with Jina Pharmaceuticals Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase-3, Randomized, Parallel Group, Open-label, Multicenter, Two-Arm Treatment Study to Evaluate the Efficacy and Safety of Weekly Paclitaxel Lipid Suspension Compared with Weekly Conventional Paclitaxel in the Patients with Platinum-Resistant/Refractory Recurrent High-grade Serous Epithelial Ovarian Cancer Including Fallopian Tube And/or Primary Peritoneal Cancer
- Lead sponsor
- Jina Pharmaceuticals Inc.
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- April 30, 2025
- Completion date
- March 31, 2026
- Enrollment
- 166 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
platinum resistant high grade epithelial ovarian cancer, platinum resistant high grade serous ovarian cancer, platinum-resistant primary peritoneal carcinoma